BriaCell Therapeutics Analyst Ratings
BriaCell Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 242.47% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 06/28/2023 | 328.08% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 02/24/2023 | 328.08% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/14/2022 | 328.08% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/03/2023 | 242.47% | HC Wainwright公司 | $25→$20 | 維護 | 買 |
| 2023年6月28日 | 328.08% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 02/24/2023 | 328.08% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 02/14/2022 | 328.08% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
What is the target price for BriaCell Therapeutics (BCTX)?
Briacell治療公司(BCTX)的目標價格是多少？
The latest price target for BriaCell Therapeutics (NASDAQ: BCTX) was reported by HC Wainwright & Co. on October 3, 2023. The analyst firm set a price target for $20.00 expecting BCTX to rise to within 12 months (a possible 242.47% upside). 3 analyst firms have reported ratings in the last year.
Briacell治療公司(納斯達克代碼：BCTX)的最新目標價是由HC Wainwright&Co.於2023年10月3日報道的。這家分析公司將目標價定為20美元，預計BCTX將在12個月內上漲至(可能上漲242.47%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?
Briacell治療公司(BCTX)的最新分析師評級是什麼？
The latest analyst rating for BriaCell Therapeutics (NASDAQ: BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics maintained their buy rating.
Briacell治療公司(納斯達克代碼：BCTX)的最新分析師評級由HC Wainwright&Co.提供，Briacell治療公司維持買入評級。
When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?
Briacell治療公司(BCTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BriaCell Treeutics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Briacell治療公司的上一次評級是在2023年10月3日提交的，所以你應該預計下一次評級將在2024年10月3日左右的某個時候提供。
Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?
分析師對Briacell Treeutics(BCTX)的評級正確嗎？
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a maintained with a price target of $25.00 to $20.00. The current price BriaCell Therapeutics (BCTX) is trading at is $5.84, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Briacell治療公司(BCTX)評級保持不變，目標價在25.00美元至20.00美元之間。BriaCell Treateutics(BCTX)目前的交易價格為5.84美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。